Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
 
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.
 
"He adds depth to Concert's management team as we progress our drug development pipeline and grow the company."
 
"Ryan has a strong track record leading a variety of financings and strategic transactions in the healthcare industry," said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. "He adds depth to Concert's management team as we progress our drug development pipeline and grow the company."
 
"This is an exciting time to be joining Concert as the company continues to advance its broad portfolio of wholly owned and partnered programs," said Ryan Daws. "I look forward to working with the Concert team to help it bring forward important new medicines."
 
Mr. Daws joins Concert with significant strategic and transactional experience within the healthcare industry. He has been involved in numerous equity and merger and acquisition transactions. Prior to joining Concert he was a Director in the Healthcare Investment Banking Group from 2010 to 2013 at Stifel, Nicolaus & Company, Inc., a financial services company. From 1999 to 2010, he served in positions of increasing responsibility within the Healthcare Investment Banking Group of Cowen and Company, LLC, a financial services firm. Mr. Daws holds a B.S. in Finance and Organizational Management from the University of South Carolina and an International M.B.A. from the University of South Carolina's Moore School of Business.
 
About Concert
 
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.
 
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
 
Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Vice President, Corporate Communications and Investor Relations

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.